良性和恶性前列腺疾病中的抗前列腺小体抗体滴度

Antiprostasome antibody titres in benign and malignant prostate disease.

作者信息

Minelli Alba, Ronquist Gunnar, Carlsson Lena, Mearini Ettore, Nilsson Ove, Larsson Anders

机构信息

Dipartimento di Medicina Sperimentale Scienze Biochimiche, Sezione di Biochimica Cellulare, Università di Perugia, Perugia, Italy.

出版信息

Anticancer Res. 2005 Nov-Dec;25(6C):4399-402.

PMID:16334115

Abstract

BACKGROUND

Prostasomes are secretory granules synthesized, stored and secreted by normal and neoplastic human prostate epithelial cells and by prostate cancer metastasis. Prostasomes are postulated to be shed into the blood circulation in prostate cancer patients, where they may cause an immune response.

MATERIALS AND METHODS

An antiprostasome antibody ELISA was developed and used to measure serum antibody titres in 81 males with prostate cancer or benign prostate hyperplasia.

RESULTS

Patients with biopsy-verified prostate cancer had significantly higher antibody titres [p = 0.019 for the dominant tumour expression (first Gleason parameter) and p = 0.022 for the dominant and non-dominant form (first and second Gleason parameters)] than individuals with benign prostate hyperplasia or other benign prostate disorders. No correlation existed between antibody titres and PSA values.

CONCLUSION

These results indicate that the antiprostasome antibody titre in serum may be a novel prostate cancer marker not replacing, but rather supplementing, PSA.

摘要

背景

前列腺小体是由正常和肿瘤性人前列腺上皮细胞以及前列腺癌转移灶合成、储存和分泌的分泌颗粒。据推测，前列腺小体在前列腺癌患者体内会进入血液循环，在那里它们可能引发免疫反应。

材料与方法

开发了一种抗前列腺小体抗体酶联免疫吸附测定法（ELISA），并用于测量81名患有前列腺癌或良性前列腺增生的男性的血清抗体滴度。

结果

经活检证实患有前列腺癌的患者，其抗体滴度显著高于患有良性前列腺增生或其他良性前列腺疾病的个体[优势肿瘤表达（第一个 Gleason 参数）时 p = 0.019，优势和非优势形式（第一个和第二个 Gleason 参数）时 p = 0.022]。抗体滴度与前列腺特异性抗原（PSA）值之间不存在相关性。